Bicara Therapeutics Inc. (BCAX) cash on hand
Bicara Therapeutics Inc. (BCAX) held cash of $414.80M at the end of fiscal 2025 (December 31, 2025). That is 15.3% lower than the $489.71M of fiscal 2024. Figures as of 18 Nov 2026, 23:15 UTC, from Yahoo Finance.
Key facts
- Cash, fiscal 2025
- $414.80M
- Change on fiscal 2024
- −15.3%
- Highest on record
- $489.71Mfiscal 2024
- Lowest on record
- $4.16Mfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
Bicara Therapeutics Inc. cash on hand, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $489.71M in fiscal 2024 and the lowest $4.16M in fiscal 2022.
Cash by fiscal year
Bicara Therapeutics Inc. cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2025 | $414.80M | 15.3% down | |
| 2024 | $489.71M | 112.5% up | |
| 2023 | $230.44M | 5,442.1% up | |
| 2022 | $4.16M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Bicara Therapeutics Inc., figure by figure
- Bicara Therapeutics Inc. market cap
- Bicara Therapeutics Inc. revenue
- Bicara Therapeutics Inc. earnings
- Bicara Therapeutics Inc. earnings per share (EPS)
- Bicara Therapeutics Inc. P/E ratio
- Bicara Therapeutics Inc. P/S ratio
- Bicara Therapeutics Inc. P/B ratio
- Bicara Therapeutics Inc. free cash flow
- Bicara Therapeutics Inc. operating margin
- Bicara Therapeutics Inc. dividend
- Bicara Therapeutics Inc. shares outstanding
- Bicara Therapeutics Inc. total debt
- Bicara Therapeutics Inc. total assets
- Bicara Therapeutics Inc. total liabilities
- Bicara Therapeutics Inc. net assets (shareholders' equity)
- Bicara Therapeutics Inc. return on equity (ROE)
- Bicara Therapeutics Inc. return on invested capital (ROIC)
Bicara Therapeutics Inc. (BCAX) overview: price, valuation and scorecard
Bicara Therapeutics Inc. cash on hand: questions and answers
How much cash does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. (BCAX) held cash of $414.80M at the end of fiscal 2025 (December 31, 2025). That is 15.3% lower than the $489.71M of fiscal 2024.
What are the highest and lowest cash figures on record for Bicara Therapeutics Inc.?
Across the 4 fiscal years on record (2022–2025), the highest was $489.71M in fiscal 2024 and the lowest $4.16M in fiscal 2022.
How is Bicara Therapeutics Inc.'s cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Bicara Therapeutics Inc. it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Bicara Therapeutics Inc. (BCAX) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/BCAX/cash
Underlying data: Yahoo Finance.